What if your doctor could tell you in real-time, with a non-invasive test as to whether or not you might be having an acute myocardial infarction (AMI) or in simpler terms, a heart attack?
When the American College of Cardiology (ACC) meets on Saturday, March 24 in Chicago, VectraCor, an emerging medical device company for cardiovascular solutions, will announce that it has received FDA approval for its ground-breaking, disruptive patented technology. The VectraplexECG System with VectraplexAMI, is the only ‘stand-alone’ cardiac monitor/ECG machine with a Cardiac Electrical Biomarker (CEB) for the real-time detection of ECG changes that may be indicative of an AMI plus the capability to derive a 15-lead ECG.
The potential to save more lives with this system is unparalleled as the immediate results allow for potentially faster treatment which protects the heart muscle from further damage, thus improving a patient’s quality of life after a heart attack.
“This is an exciting, non-invasive, real-time technology that will benefit many patients and may help clinicians diagnose more quickly the number one disease in the world, which potentially can become the new standard of care in cardiac monitoring,” said Brad S. Schreck, President & CEO of VectraCor.
The current “gold standard” for AMI detection is a long process which can continue up to 24 hours and involves placing 10 electrodes to produce a 12-lead ECG and measure serum biomarkers every 4-6 hours via invasive blood draws. The VectraplexECG System uses only 5 electrodes to detect ECG changes suggestive of AMI and derive a 15-lead ECG. This makes placing the electrodes on a patient much easier, more cost-effective and potentially reduces placement error.
VectraCor is at the forefront of the mHealth revolution with plans to incorporate this technology into other devices such as stress test systems and mobile ambulatory “Holters/Event Monitors” that will allow real-time monitoring
between doctor and patient via the Verizon Wireless Network. www.vectracor.com